Breaking AI & Tech News Analyzed

Revolutionary Lupus Treatment Five lupus patients in England are in remission after being treated with a revolutionary therapy that genetically modifies their own cells, in a medical breakthrough that could offer people a cure, doctors have said. How CAR T-Cell Therapy Works CAR (chimeric antigen receptor) T-cell therapy involves removing a type of white blood cell also called T lymphocytes, which are crucial for hunting out infected or damaged cells, and engineering them to spot and destroy disease. The T-cells are then fed back into the patient via an infusion to reset their immune system. The NHS Trial In an NHS trial led by University College London hospitals foundation trust (UCLH) and University College London (UCL), nine patients with severe lupus were recruited. They had not previously responded to any treatments. Most had lupus nephritis, a serious complication involving the kidneys. Six patients received a lower dose of CAR-T and three got a higher dose. Five of those on the lower dose, who were followed up for an average of 11 months, went into remission within just a few months. Patient Success Stories One of the five patients, Katie Tinkler, said she no longer had any of the main symptoms of the disease more than three decades after her diagnosis. Tinkler has also skied for the first time in a decade and was able to dance at her daughter’s wedding. The Future of Lupus Treatment CAR T-cell therapy, which patients only need to have once, could transform lupus treatment and remove the need for lifelong medication, doctors said. Prof Karl Peggs, the director of UCLH’s biomedical research centre, said that while larger studies were needed, CAR T-cell therapy could offer people the chance of a cure.

Sam Neill's Cancer-Free Announcement Sam Neill, the renowned actor from Jurassic Park, has shared the news that he is now cancer-free. This comes after he participated in a CAR T-cell therapy clinical trial in Australia, a treatment he turned to when chemotherapy stopped working on his stage-three blood cancer. The Journey to CAR T-Cell Therapy Neill's cancer journey began about five years ago when he was diagnosed with stage-three angioimmunoblastic T-cell lymphoma. Initially, he was on chemotherapy, which, although 'miserable,' was keeping him alive. However, when chemotherapy ceased to be effective, Neill's situation became critical. It was then that he turned to a CAR T-cell therapy clinical trial focused on his type of lymphoma. Understanding CAR T-Cell Therapy CAR T-cell therapy is a form of cancer immunotherapy that involves taking T-cells (a type of white blood cell) from a patient, genetically engineering them to target and kill cancer cells, growing these modified T-cells in a laboratory, and then infusing them back into the patient. This treatment has shown significant success in treating certain types of blood cancers. The Impact and Future of CAR T-Cell Therapy Neill's successful treatment is a beacon of hope for many. He is now advocating for CAR T-cell therapy to be made more widely available in Australia, alongside the not-for-profit blood cancer foundation Snowdome. Currently, this therapy is only available under Australia's public health system for certain cancers at specific hospitals, and it is extremely costly when accessed privately, with prices upwards of A$600,000 per patient. Advocacy and Gratitude Neill expressed his gratitude to the scientists who helped him and emphasized the importance of making such treatments available to everyone who needs them, not just in Australia but worldwide. His journey and advocacy highlight the critical need for accessible and innovative cancer treatments.